These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33762108)

  • 1. What are the molecular mechanisms driving the switch from MPNs to leukemia?
    Wang X; Hoffman R
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
    Pasca S; Chifotides HT; Verstovsek S; Bose P
    Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1-negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia-related.
    Chen D; Geyer J; Bagg A; Hasserjian R; Weinberg OK
    Int J Lab Hematol; 2024 Aug; 46(4):687-694. PubMed ID: 38665121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
    Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
    Ajufo HO; Waksal JA; Mascarenhas JO; Rampal RK
    Ther Adv Hematol; 2023; 14():20406207231177282. PubMed ID: 37564898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
    Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
    Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clonal evolution in myeloproliferative neoplasms].
    Yoshida K
    Rinsho Ketsueki; 2024; 65(8):784-789. PubMed ID: 39231709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
    Abruzzese E; Niscola P
    Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase.
    Wang X; Rampal RK; Hu CS; Tripodi J; Farnoud N; Petersen B; Rossi MR; Patel M; McGovern E; Najfeld V; Iancu-Rubin C; Lu M; Davis A; Kremyanskaya M; Weinberg RS; Mascarenhas J; Hoffman R
    JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35259128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
    He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
    Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
    Kundranda MN; Tibes R; Mesa RA
    Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Mannelli F; Guglielmelli P; Fazi P; Crea E; Piciocchi A; Vignetti M; Amadori S; Pane F; Venditti A; Vannucchi AM
    Future Oncol; 2023 Jan; 19(2):103-111. PubMed ID: 36651780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-existence of mutations in myeloproliferative neoplasms and their clinical significance: a prognostic approach.
    Homaei Hadad E; Pezeshki SMS; Shahrabi S; Saki Malehi A; Saki N
    Expert Rev Hematol; 2020 Nov; 13(11):1289-1301. PubMed ID: 32886563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated and blast phase myeloproliferative neoplasms.
    Saliba AN; Gangat N
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms.
    Celik H; Krug E; Zhang CR; Han W; Issa N; Koh WK; Bjeije H; Kukhar O; Allen M; Li T; Fisher DAC; Fowles JS; Wong TN; Stubbs MC; Koblish HK; Oh ST; Challen GA
    Cancer Discov; 2021 Dec; 11(12):3126-3141. PubMed ID: 34193440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
    Calabresi L; Carretta C; Romagnoli S; Rotunno G; Parenti S; Bertesi M; Bartalucci N; Rontauroli S; Chiereghin C; Castellano S; Gentili G; Maccari C; Vanderwert F; Mannelli F; Della Porta M; Manfredini R; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2023 Oct; 98(10):1520-1531. PubMed ID: 37399248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
    Zhang SJ; Rampal R; Manshouri T; Patel J; Mensah N; Kayserian A; Hricik T; Heguy A; Hedvat C; Gönen M; Kantarjian H; Levine RL; Abdel-Wahab O; Verstovsek S
    Blood; 2012 May; 119(19):4480-5. PubMed ID: 22431577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukemia secondary to myeloproliferative neoplasms.
    Dunbar AJ; Rampal RK; Levine R
    Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.